Financial Position and Performance - As of March 31, 2022, the financial assets at fair value through profit or loss for the Global X MSCI China ETF amounted to HK$525,189,619, while the Global X Hang Seng High Dividend Yield ETF was HK$564,198,146, Global X CSI 300 ETF was HK$29,558,796, Global X China Biotech ETF was HK$963,477,060, and Global X China Cloud Computing ETF was HK$483,252,072[13]. - The total net assets attributable to unitholders for the sub-funds were not explicitly stated in the provided content, but the financial assets indicate significant holdings across various sectors[13]. - Total assets amounted to HK$80,508,390,000, with liabilities at HK$54,072,220,000, resulting in equity of HK$26,436,170,000[33]. - The company reported a profit after tax of HK$286,718,905, reflecting a comprehensive income increase compared to the previous year[37]. - The company experienced a significant increase in net assets attributable to unitholders, totaling HK$995,159,184[40]. - The total income from financial assets at fair value through profit was reported at HK$297,472,750[37]. Audit and Compliance - The financial statements for the year ended March 31, 2022, were audited in accordance with International Financial Reporting Standards (IFRSs) and were found to give a true and fair view of the financial position of each sub-fund[8]. - The independent auditor's report confirmed that the financial statements were properly prepared in accordance with the relevant disclosure provisions of the Trust Deed and the SFC Code[28]. - The management of the sub-funds is responsible for ensuring that the financial statements are free from material misstatement, whether due to fraud or error[20]. - The audit included an assessment of key controls over the existence and valuation of financial assets, with no material exceptions found during testing[16]. - The engagement partner for the audit was Mr. Chau Chi Kit from PricewaterhouseCoopers, indicating a reputable auditing firm was involved in the process[29]. Fund Management and Strategy - The company plans to expand its market presence, focusing on new product development and technology advancements[33]. - Future guidance indicates a positive outlook for revenue growth, driven by strategic market expansions and potential acquisitions[33]. - The company aims to enhance operational efficiency through cost management strategies, targeting a reduction in overall expenses[37]. Fund Performance and Income - Global X MSCI China ETF reported a loss before tax of HK$285,771,734 for 2022, compared to a profit of HK$305,952,519 in 2021, indicating a significant decline in performance[42]. - The net cash flows generated from operating activities for Global X MSCI China ETF decreased to HK$130,494,985 in 2022 from HK$156,945,065 in 2021, reflecting a drop of approximately 17%[42]. - Global X Hang Seng High Dividend Yield ETF experienced a profit before tax of HK$9,024,104 in 2022, down from HK$33,445,362 in 2021, showing a decline of about 73%[44]. - Global X CSI 300 ETF reported a loss before tax of RMB6,094,136 in 2022, compared to a profit of RMB24,160,011 in 2021, indicating a substantial downturn[46]. - The net cash flows generated from operating activities for Global X China Biotech ETF were RMB826,524,234 in 2022, a recovery from a loss of RMB1,151,950,213 in 2021[48]. - Global X China Cloud Computing ETF reported a loss before tax of RMB566,331,340 in 2022, compared to a profit of RMB206,020,858 in 2021, indicating a significant decline[50]. Financial Assets and Valuation - The financial assets of the sub-funds are classified as either measured at amortized cost or at fair value through profit or loss (FVPL)[69]. - The fair value measurement of financial instruments is based on quoted last traded market prices within the bid-ask spread[86]. - The Sub-Funds' net assets attributable to unitholders are calculated based on the total assets minus liabilities, classified as equity under IFRSs[109]. - The expected credit losses (ECLs) for debt instruments not held at fair value through profit or loss are based on the difference between contractual cash flows and expected cash flows, discounted at the original effective interest rate[103]. - ECLs are recognized in two stages: a 12-month ECL for exposures without significant credit risk increase, and a lifetime ECL for those with significant credit risk increase[104]. Unit Transactions and NAV - The number of units in issue at the end of the year was 17,600,000, with a net asset value of HK$526,436,175[40]. - As of March 31, 2022, the Accounting NAV for the MSCI China ETF was HK$526,436,175, a decrease of 47% from HK$995,159,184 in 2021[113]. - The Hang Seng High Dividend Yield ETF reported an Accounting NAV of HK$564,778,840, up from HK$98,530,157 in 2021, indicating a significant increase[113]. - The China Biotech ETF's Accounting NAV decreased to RMB963,501,712 from RMB2,490,238,419, reflecting a decline of approximately 61%[113]. - The China Cloud Computing ETF's Accounting NAV fell to RMB483,934,722 from RMB1,080,395,975, a decrease of about 55%[113]. Fees and Expenses - Management fees totaled HK$1,444,824, with trustee fees at HK$183,550,965, contributing to overall expenses of HK$17,044,867[37]. - The management fee for the Manager is calculated at an annual rate based on the Dealing NAV of the Sub-Funds, accrued daily and payable monthly[126]. - MSCI China ETF management fee for 2022 was HK$1,444,824, a significant increase from HK$571,054 in 2021[127]. - Hang Seng High Dividend Yield ETF management fee for 2022 was HK$1,125,043, up from HK$218,837 in 2021[127]. - China Biotech ETF management fee for 2022 reached RMB 11,591,023, compared to RMB 9,166,612 in 2021, indicating a growth of approximately 26%[127]. - China Cloud Computing ETF management fee for 2022 was RMB 4,936,366, a decrease from RMB 5,886,935 in 2021[127]. Market and Investment Strategy - The MSCI China ETF aims to closely correspond to the performance of the MSCI China Index by investing substantially all assets in index securities[55]. - The Hang Seng High Dividend Yield ETF targets performance alignment with the Hang Seng High Dividend Yield Index[56]. - The CSI 300 ETF is designed to reflect the performance of the CSI 300 Index, with stock codes for both Renminbi and Hong Kong dollar counters[57]. - The China Biotech ETF seeks to mirror the performance of the Solactive China Biotech Index NTR[58]. - The China Cloud Computing ETF aims to replicate the performance of the Solactive China Cloud Computing Index NTR[59].
中绿(00904) - 2022 - 年度财报